联系方式
Paul England

Paul England, DPhil

高级专业支持律师

Read More
联系方式
Paul England

Paul England, DPhil

高级专业支持律师

Read More

2020年9月30日

Paul England discusses IP and pharma changes of the past decade, for Intellectual Property Magazine

Just a decade ago, during the financial crisis, the life sciences sector, dominated by small-molecule pharmaceuticals, was being squeezed.

On the one hand, pharma was finding it harder to identify small-molecule targets and match them with candidate drugs. On the other, it was meeting the challenge of generic competition to the ‘blockbuster’ drugs that had driven the market in the previous decade.

Paul outlines the recent changes in the life sciences sector, including the advance of technology and the implication for patents.

Read the full version originally published in the October edition of Intellectual Property Magazine (subscription required).

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

酒店与休闲

Paul England writes on COVID-19 drug supply and patent system for Manufacturing Chemist

2020年8月6日

作者 Paul England, DPhil

点击此处了解更多